Trial Profile
The First-In-Man Safety and Performance Evaluation of the Biomime Sirolimus Eluting Stent System for the Treatment of Patients With Single, De Novo, Non-Complex Coronary Lesions-The Biomime Pilot FiM Trial.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Ischaemia
- Focus Therapeutic Use
- Acronyms meriT-1
- Sponsors Meril Life Sciences
- 18 Jan 2012 New trial record